We report our experience with next-generation sequencing to characterize the landscape of actionable genomic alterations in renal cell carcinoma (RCC).
A query of our institutional clinical sequencing database (MSK-IMPACT) was performed which included tumor samples from 38,468 individuals across all cancer types.